Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer

Por Viteri, Santiago, González-Cao, María, Barrón, Feliciano, Riso, Aldo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials—are we in a new era?

Por Clarke, Jeffrey M., Wang, Xiaofei, Ready, Neal E.
Publicado no Transl Lung Cancer Res (2015)

Treatment for small cell lung cancer, where are we now?—a review

Por Alvarado-Luna, Gabriela, Morales-Espinosa, Daniela
Publicado no Transl Lung Cancer Res (2016)

The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung

Por Tan, Wan Ling, Ng, Quan-Sing
Publicado no Transl Lung Cancer Res (2016)

Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases

Por Yang, T. Jonathan, Wu, Abraham J.
Publicado no Transl Lung Cancer Res (2016)

Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that’s the question

Por Gridelli, Cesare, Casaluce, Francesca, Sgambato, Assunta, Monaco, Fabio, Guida, Cesare
Publicado no Transl Lung Cancer Res (2016)

Non-small cell lung cancer: current treatment and future advances

Por Zappa, Cecilia, Mousa, Shaker A.
Publicado no Transl Lung Cancer Res (2016)

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives

Por O’Kane, Grainne M., Leighl, Natasha B.
Publicado no Transl Lung Cancer Res (2016)

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Por Bos, Marc, Gardizi, Masyar, Schildhaus, Hans-Ulrich, Buettner, Reinhard, Wolf, Juergen
Publicado no Transl Lung Cancer Res (2013)

From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience

Por Muley, Thomas R., Herth, Felix JF., Schnabel, Philipp A., Dienemann, Hendrik, Meister, Michael
Publicado no Transl Lung Cancer Res (2012)

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients

Por Majem, Margarita, Remon, Jordi
Publicado no Transl Lung Cancer Res (2013)

International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature

Por Kratz, Johannes R., Mann, Michael J., Jablons, David M.
Publicado no Transl Lung Cancer Res (2013)

Clinical trials for lung cancer in China

Por Niu, Fei-Yu, Zhong, Wen-Zhao, Zhou, Qing, Wu, Yi-Long
Publicado no Transl Lung Cancer Res (2014)

Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy

Por Butts, Charles A.
Publicado no Transl Lung Cancer Res (2013)

Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer

Por Tofts, Ryu Peter Hambrook, Lee, Peter MJ, Sung, Arthur Wai
Publicado no Transl Lung Cancer Res (2013)

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Por Teixidó, Cristina, Karachaliou, Niki, Peg, Vicente, Gimenez-Capitan, Ana, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2014)

Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC

Por Das, Millie, Wakelee, Heather
Publicado no Transl Lung Cancer Res (2014)

Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?

Por Cascales, Almudena, Martinetti, Florent, Belemsagha, Deborah, Le Pechoux, Cecile
Publicado no Transl Lung Cancer Res (2014)

Lung cancer vaccines: current status and future prospects

Por Ramlogan-Steel, Charmaine A., Steel, Jason C., Morris, John C.
Publicado no Transl Lung Cancer Res (2014)

Notch signaling: a hero or villain in the war against cancer?

Por Chikara, Shireen, Reindl, Katie M.
Publicado no Transl Lung Cancer Res (2013)